Synthesis and cancer antiproliferative activity of new histone deacetylase inhibitors: hydrophilic hydroxamates and 2-aminobenzamide-containing derivatives

European Journal of Medicinal Chemistry

Volumn 41, Issue 6, 2006, Pages 697-708

  Nagaoka, Y ^a   Maeda, T ^a   Kawai, Y ^a   Nakashima, D ^a   Oikawa, T ^a   Shimoke, K ^a   Ikeuchi, T ^a   Kuwajima, H ^b   Uesato, S ^a  

^a KANSAI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY   (Japan)

Author keywords

2 Aminobenzamide containing HDAC inhibitor; Anticancer drug; Histone deacetylase inhibitor; Hydrophilic hydroxamate HDAC inhibitor; Plasma stability; Tandem mass spectrometry

Indexed keywords

2 AMINOBENZAMIDE; 4 [[(1,3 BENZODIOXOL 5 YLMETHYL) (2 HYDROXYETHYL)AMINO]METHYL]N HYDROXYBENZAMIDE; 4 N ACETYLDINALINE; ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [[(1,3 BENZODIOXAZOL 5 YLMETHYL) (2 HYDROXYETHYL)AMINO]METHYL]BENZAMIDE; N (2 AMINOPHENYL) 4 [[(2 HYDROXYETHYL) (3 PYRIDINYLMETHYL)AMINO]METHYL] BENZAMIDE; N (2 AMINOPHENYL) 4 [[(2 HYDROXYETHYL) (4 METHOXYBENZYL)AMINO]METHYL] BENZAMIDE; N (2 AMINOPHENYL) 4 [[(2 HYDROXYETHYL) [(1 METHYL 1H INDOL 3 YL)METHYL]AMINO]METHYL]BENZAMIDE; N (2 AMINOPHENYL) 4 [[(3,4 DIFLUOROBENZYL) (2 HYDROXYETHYL)AMINO]METHYL] BENZAMIDE; N (2 AMINOPHENYL) 4 [[BENZYL(2 HYDROXYETHYL)AMINO]METHYL]BENZAMIDE; N HYDROXY 4 [[(2 HYDROXYETHYL) (2 NAPHTHYLMETHYL)AMINO]METHYL]BENZAMIDE; N HYDROXY 4 [[(2 HYDROXYETHYL) (3 PYRIDIINYLMETHYL)AMINO]METHYL]BENZAMIDE; N HYDROXY 4 [[(2 HYDROXYETHYL) (3 QUINOLINYLMETHYL)AMINO]METHYL]BENZAMIDE; N HYDROXY 4 [[(2 HYDROXYETHYL) [2 (1H INDOLE 3 YL)ETHYL]AMINO]METHYL] BENZAMIDE; UNCLASSIFIED DRUG; VORINOSTAT; ZINC; ANTHRANILIC ACID DERIVATIVE; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FIBROBLAST; HUMAN; HUMAN CELL; HYDROPHILICITY; PLASMA; TOXICITY; BLOOD; DRUG ANTAGONISM; INFRARED SPECTROPHOTOMETRY; MASS SPECTROMETRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

ANTHRANILIC ACIDS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SPECTROPHOTOMETRY, INFRARED;

EID: 33744991044     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2006.02.002     Document Type: Article

References (26)

1. Pazin M.J., and Kadonaga J.T. Cell 89 (1997) 325-328
2. Pennisi E. Science 275 (1997) 155-157
3. Bouchain G., and Delorme D. Curr. Med. Chem. 10 (2003) 2359-2372
4. Curtin M.L. Curr. Opin. Drug Discov. Devel. 7 (2004) 848-868
5. Weinmann H., and Ottow E. Annu. Rep. Med. Chem. 39 (2004) 185-196
6. Biel M., Wascholowski V., and Giannis A. Angew. Chem. Int. Ed. Engl. 44 (2005) 3186-3216
7. Monneret C. Eur. J. Med. Chem. 40 (2005) 1-13
8. Adams J., and Elliott P.J. Oncogene 19 (2000) 6687-6692
9. Kelly W.K., Richon V.M., O'Connor O., Curley T., MacGregor-Curtelli B., Tong W., Klang M., Schwartz L., Richardson S., Rosa E., Drobnjak M., Cordon-Cordo C., Chiao J.H., Rifkind R., Marks P.A., and Scher H. Clin. Cancer Res. 9 (2003) 3578-3588
10. Nakajima H., Kim Y.B., Terano H., Yoshida M., and Horinouchi S. Exp. Cell Res. 241 (1998) 126-133
11. Piekarz R.L., Robey R., Sandor V., Bakke S., Wilson W.H., Dahmoush L., Kingma D.M., Truner M.L., Altemus R., and Bates S.E. Blood 98 (2001) 2865-2868
12. Sandor V., Bakke S., Robey R.W., Kang M.H., Blagosklonny M.V., Bender J., Brooks R., Piekarz R.L., Tucker E., Figg W.D., Chan K.K., Goldspiel B., Fojo A.T., Balcerzak S.P., and Bates S.E. Clin. Cancer Res. 8 (2002) 718-728
13. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., Suzuki T., Tsuruo T., and Nakanishi O. Proc. Natl. Acad. Sci. USA 96 (1999) 4592-4597
14. Pyan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. J. Clin. Oncol. 23 (2005) 3912-3922
15. Prakash S., Foster B.J., Meyer M., Wozniak A., Heilbrun L.K., Flaherty L., Zalupski M., Radulovic L., Valdivieso M., and LoRusso P.M. Invest. New Drugs 19 (2001) 1-11
16. Pauer L.R., Olivares J., Cunningham C., Williams A., Grove W., Kraker A., Olson S., and Nemunaitis J. Cancer Invest. 22 (2004) 886-896
17. Remiszewski S.W., Sambucetti L.C., Bair K.W., Bontempo J., Cesarz D., Chandramouli N., Chen R., Cheung M., Cornell-Kennon S., Dean K., Diamantidis G., France D., Green M.A., Howell K.L., Kashi R., Kwon P., Lassota P., Martin M.S., Mou Y., Perez L.B., Sharma S., Smith T., Sorensen E., Taplin F., Trogani N., Versace R., Walker H., Weltchek-Engler S., Wood A., Wu A., and Atadja P. J. Med. Chem. 46 (2003) 4609-4624
18. Catley L., Weisberg E., Tai Y.T., Atadja P., Remiszewski S., Hideshima T., Mitsiades N., Shringarpure R., LeBlanc R., Chauhan D., Munshi N.C., Schlossman R., Richardson P., Griffin J., and Anderson K.C. Blood 102 (2003) 2615-2622
19. Uesato S., Kitagawa M., Nagaoka Y., Maeda T., Kuwajima H., and Yamori T. Bioorg. Med. Chem. Lett. (Jpn.) 12 (2002) 1347-1349
20. Maeda T., Nagaoka Y., Kuwajima H., Seno C., Maruyama S., Kurotaki M., and Uesato S. Bioorg. Med. Chem. 12 (2004) 4351-4360
21. Maeda T., Nagaoka Y., Kawai Y., Takagaki N., Yasuda C., Yogosawa S., Sowa Y., Sakai T., and Uesato S. Biol. Pharm. Bull. 28 (2005) 849-853
22. Weinmann H., and Ottow E. Annu. Rep. Med. Chem. 39 (2004) 185-196
23. SAHA and MS-275 were synthesized at the laboratory of Kansai University for the assays.
24. Suzuki T., Ando T., Tsuchiya K., and Fukazawa N. J. Med. Chem. 42 (1999) 3001-3003
25. Khan S., Ahmad A., and Ahmad I. Biomed. Chromatogr. 17 (2003) 493-499
26. H. Mori, K. Sakamoto, Y. Tsurumi, S. Takase, M. Hino, WO 00/21979, 2000; Chem. Abstr. 2000, 132, 288796.